January 10, 2022
Collaboration will combine Carisma’s engineered macrophage technology with Moderna’s mRNA and LNP technologies to generate and develop in vivo CAR-M therapeutics Multi-year research collaboration funded by Moderna with options for up to twelve targets Carisma to receive $45 million up-front cash payment and investment by Moderna in the form of a $35...
January 5, 2022
PHILADELPHIA, Jan. 5, 2022 /PRNewswire/ -- Carisma Therapeutics Inc., a biopharmaceutical pioneer in engineered macrophage-based therapeutics, today announced that Steven Kelly, President and Chief Executive Officer of Carisma, will present at the 40th Annual J.P. Morgan Healthcare Conference. The presentation will take place virtually on January 12, 2022, at 7:30 am ET, and will be accessible to...
December 6, 2021
PHILADELPHIA, December 2, 2021 -- Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that it has entered into a clinical study collaboration with Merck (known as MSD outside the US and Canada) to evaluate their proprietary targeted chimeric antigen receptor macrophages...
November 29, 2021
PHILADELPHIA, November 29, 2021 – Carisma Therapeutics, a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that Sanford (Sandy) Zweifach has been appointed to the chairman position for the Board of Directors. Mr. Zweifach joins Carisma as a senior executive with 30 years in the...
November 12, 2021
PHILADELPHIA, November 12, 2021, 12:10 PM ET-- Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, presented today for the first time preliminary findings from the landmark Phase 1 multi-center clinical trial of CT-0508, a human epidermal growth factor receptor 2 (HER2) targeted chimeric...
November 1, 2021
PHILADELPHIA, November 1, 2021 -- CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today the acceptance of a late breaker abstract for oral presentation of its clinical study data and three pre-clinical study abstracts to be presented at the upcoming Society for...
